{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:19:48Z","timestamp":1785320388439,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"S6","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["MMW - Fortschritte der Medizin"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s15006-022-0959-z","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T23:04:26Z","timestamp":1650582266000},"page":"11-17","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Diagnostik, Therapie und die Bedeutung der Lebensqualit\u00e4t von Patienten mit chronischem Koronarsyndrom","Diagnostics, therapy and the importance of quality of life in patients with chronic coronary syndrome. Results oft the general practitioner care study ALTHEA"],"prefix":"10.1007","volume":"164","author":[{"given":"Ralf","family":"Dechend","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"key":"959_CR5608","doi-asserted-by":"crossref","unstructured":"Knuuti J et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41(3):407-477","DOI":"10.1093\/eurheartj\/ehz425"},{"key":"959_CR5612","unstructured":"Ford TJ et al. Stable coronary syndromes: pathophysiology, diagnostic advances and therapeutic need. Heart 2018;104(4):284-292"},{"key":"959_CR5618","doi-asserted-by":"crossref","unstructured":"Regitz-Zagrosek V. Geschlechterspezifische Aspekte bei chronischer koronarer Herzkrankheit im Praxisalltag - Ergebnisse der Versorgungsstudie AURORA. MMW Fortschr Med 2020;162(S5):21-27","DOI":"10.1007\/s15006-020-0660-z"},{"key":"959_CR5622","doi-asserted-by":"crossref","unstructured":"Beltrame JF et al. The prevalence of weekly angina among patients with chronic stable angina in primary care practices: The Coronary Artery Disease in General Practice (CADENCE) Study. Arch Intern Med 2009;169(16):1491-1499","DOI":"10.1001\/archinternmed.2009.295"},{"key":"959_CR5626","unstructured":"Ebell MH. Evaluation of chest pain in primary care patients. Am Fam Physician 2011;83(5):603-605"},{"key":"959_CR5630","doi-asserted-by":"crossref","unstructured":"Manolis AJ et al. Impact of stable angina on    health status and quality of life perception of currently treated patients. The BRIDGE 2 survey. Eur J Intern Med 2019;70:60-67","DOI":"10.1016\/j.ejim.2019.09.013"},{"key":"959_CR5634","doi-asserted-by":"crossref","unstructured":"Borr\u00e1s X et al. Stable angina in Spain and its impact on quality of life. The AVANCE registry. Rev Esp Cardiol 2012;65(8):734-741","DOI":"10.1016\/j.rec.2012.03.010"},{"key":"959_CR5638","unstructured":"Nationale VersorgungsLeitlinie Chronische KHK - Langfassung, 5. Auflage. Version 1, 2019"},{"key":"959_CR5642","doi-asserted-by":"crossref","unstructured":"Jones MM et al. Patients' descriptions of angina symptoms: a qualitative study of primary care patients. Br J Gen Pract 2010;60(579):735-741","DOI":"10.3399\/bjgp10X532378"},{"key":"959_CR5648","doi-asserted-by":"crossref","unstructured":"Qintar M et al. Effect of angina under-recognition on treatment in outpatients with stable ischaemic heart disease. Eur Heart J 2016;2(3):208-214","DOI":"10.1093\/ehjqcco\/qcw016"},{"key":"959_CR5652","doi-asserted-by":"crossref","unstructured":"Arnold SV et al. Predictors of physician under-recognition of angina in outpatients with stable coronary artery disease. Circulation 2016;9(5):554-559","DOI":"10.1161\/CIRCOUTCOMES.116.002781"},{"key":"959_CR5656","doi-asserted-by":"crossref","unstructured":"Shafiq A et al. Patient and physician discordance in reporting symptoms of angina among stable coronary artery disease patients: Insights from the Angina Prevalence and Provider Evaluation of Angina Relief (APPEAR) study. Am Heart J 2016;175:94-100","DOI":"10.1016\/j.ahj.2016.02.015"},{"key":"959_CR5660","doi-asserted-by":"crossref","unstructured":"Lichtman JH et al. Sex differences in the presentation and perception of symptoms among young patients with myocardial infarction: evidence from the VIRGO study (variation in recovery: role of gender on outcomes of young AMI patients). Circulation 2018;137(8):781-790","DOI":"10.1161\/CIRCULATIONAHA.117.031650"},{"key":"959_CR5670","doi-asserted-by":"crossref","unstructured":"Ferrari R et al. Anti-anginal drugs - beliefs and evidence: systematic review covering 50 years of medical treatment. Eur Heart J 2019;40(2):190-194","DOI":"10.1093\/eurheartj\/ehy504"},{"key":"959_CR5676","doi-asserted-by":"crossref","unstructured":"Ford TJ and Berry C. Angina: contemporary diagnosis and management. Heart 2020;106(5):387-398","DOI":"10.1136\/heartjnl-2018-314661"},{"key":"959_CR5682","doi-asserted-by":"crossref","unstructured":"Chaitman BR et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004;291(3):309-316","DOI":"10.1001\/jama.291.3.309"},{"key":"959_CR5687","doi-asserted-by":"crossref","unstructured":"Chaitman BR et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43(8):1375-1382","DOI":"10.1016\/j.jacc.2003.11.045"},{"key":"959_CR5691","doi-asserted-by":"crossref","unstructured":"Wilson SR et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol 2009;53(17):1510-1516","DOI":"10.1016\/j.jacc.2009.01.037"},{"key":"959_CR5695","doi-asserted-by":"crossref","unstructured":"Fox K et al. Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study. Eur Heart J 2015;36(46):3291-3296","DOI":"10.1093\/eurheartj\/ehv451"}],"container-title":["MMW - Fortschritte der Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15006-022-0959-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15006-022-0959-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15006-022-0959-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:06:13Z","timestamp":1650585973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.springermedizin.de\/doi\/10.1007\/s15006-022-0959-z"}},"subtitle":["Ergebnisse der haus\u00e4rztlichen Versorgungsstudie ALTHEA"],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":19,"journal-issue":{"issue":"S6","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["959"],"URL":"https:\/\/doi.org\/10.1007\/s15006-022-0959-z","relation":{},"ISSN":["1438-3276","1613-3560"],"issn-type":[{"value":"1438-3276","type":"print"},{"value":"1613-3560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"22 April 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Prof.   Dechend erhielt Vortrags- und Beratungshonorare von Berlin-Chemie, Servier und Bayer. Die Studie wurde von der Berlin-Chemie AG finanziell unterst\u00fctzt. Das Unternehmen zusammen mit A.MENARINI I.F.R. S.r.l. sprach keine Empfehlungen aus und hatte keinen Einfluss auf die Erstellung des Manuskripts, die Auswahl der verwendeten Literatur oder die Entscheidung, das Manuskript zur Ver\u00f6ffentlichung einzureichen.    Das Unternehmen hatte die M\u00f6glichkeit, vor Einreichung der endg\u00fcltigen Fassung Kommentare zum Manuskript abzugeben. Alle im Artikel getroffenen Aussagen entsprechen ausschlie\u00dflich den Ansichten des Verfassers.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}